Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2011

View Archived Issues

New phase I/II data on vector-based malaria vaccines

Preclinical data support advancement of new Servier product to clinic

Intellikine divulges preclinical data on INK-1117

New phosphodiesterase 10A inhibitors claimed

Novel serine/threonine-protein kinase ATR inhibitors prepared by Vertex

Belgian authorities clear phase I/II combination treatment study in metastatic melanoma

FDA grants standard review status for carfilzomib NDA

First data reported on Graspa in older patients with Ph- ALL

CSF-1-R-targeted antibody shows promise in proof-of-principle study

Pharmaxis reaches recruitment target in Bronchitol trial

Arcarios receives loan to develop osteoarthritis drug candidate

Chinese organizations patent new anticancer agents

Anacor Pharmaceuticals reports phase IIa data on AN-2728 and AN-2898

Novel pancreatic cancer vaccine enters clinic

Ablynx and Merck Serono select Nanobody for preclinical development

Celladon heart failure therapy receives FDA fast track status

Genentech begins first-in-human study of IL-17-directed antibody

Geron begins phase II study of GRN-1005

New inhibitors of cytokine signaling designed in U.S.

Eisai reports new agents with antitumor potential

MicroRNA therapeutics discovery effort begins in glioblastoma multiforme

Novel histamine H3 receptor antagonists/inverse agonists reported

Repros Therapeutics reports topline data on Androxal in hypogonadism and type 2 diabetes

Cubist Pharmaceuticals acquires Adolor

Transition Therapeutics begins phase I TT-401 trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...